サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1747691

軸性脊椎関節炎（AXSPA）の世界市場

Axial Spondyloarthritis (AXSPA)

出版日
ページ情報
英文 182 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
軸性脊椎関節炎（AXSPA）の世界市場
出版日: 2025年06月13日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 182 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

軸性脊椎関節炎（AXSPA）の世界市場は2030年までに84億米ドルに達する

2024年に64億米ドルと推定される軸性脊椎関節炎（AXSPA）の世界市場は、2024～2030年の分析期間においてCAGR 4.6%で成長し、2030年には84億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである強直性脊椎炎は、CAGR 3.7%を記録し、分析期間終了時には53億米ドルに達すると予測されます。非放射線学的軸性脊椎関節炎セグメントの成長率は、分析期間中CAGR 6.4%と推定されます。

米国市場は17億米ドル、中国はCAGR 7.2％で成長すると予測

米国の軸性脊椎関節炎（AXSPA）市場は、2024年に17億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに16億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.2%と4.6%と予測されています。欧州では、ドイツがCAGR 2.9%で成長すると予測されています。

世界の軸性脊椎関節炎（AXSPA）市場- 主要動向と促進要因まとめ

早期診断と長期的な治療管理が必要な高負担の慢性疾患として、軸性脊椎関節炎の認知度が高まっている理由とは？

軸性脊椎関節炎（AXSPA）は、その有病率と患者のQOLに与える長期的な影響が広く認識されるようになり、臨床的にも商業的にも注目が高まっています。この炎症性リウマチ性疾患は主に脊椎と仙腸関節を侵し、慢性的な背部痛、こわばり、可動性の低下として現れます。AxSpAは、その身体障害性にもかかわらず、非炎症性背部痛との症状の重複や、画像に基づく早期の確認の欠如のため、何年もの間、過小診断または誤診のままです。

この疾患には、放射線性AxSpA（強直性脊椎炎）と非放射線性AxSpAという2つのサブセットがあり、どちらも適切に管理されなければ、脊椎癒合や不可逆的な関節損傷へと進行する可能性があります。働き盛りの成人への負担は特に大きく、機能障害、疲労、ぶどう膜炎、乾癬、炎症性腸疾患などの合併症が、ヘルスケアをさらに複雑にしています。これらの要因は、早期かつ正確な診断と、疾患修飾療法への持続的なアクセスの必要性を強調しています。

認知度向上キャンペーン、MRIを用いた診断プロトコルの改善、リウマチ学会による臨床ガイドラインの改訂は、医療システム全体におけるAxSpAの認知度向上に寄与しています。より多くの患者が疾患初期の段階で発見されるにつれ、効果的で長期的な治療法に対する需要が高まっています。支払者とヘルスケアプロバイダーは、AxSpAを、統合ケアモデル、長期モニタリング、アウトカム主導の治療最適化を必要とする優先的な慢性疾患として扱うようになってきています。

生物学的治療、精密診断、および治療ガイドラインは、AxSpAにおける患者の転帰をどのように前進させているか？

生物学的製剤、特に腫瘍壊死因子（TNF）阻害剤とインターロイキン-17（IL-17）阻害剤は、非ステロイド性抗炎症薬で十分な効果が得られない患者に対するAxSpA治療の要となっています。これらの薬剤は、炎症を抑えて症状を緩和するだけでなく、構造的損傷の進行を遅らせる効果もあります。secukinumabやixekizumabのようなIL-17阻害剤は、放射線照射型と非放射線照射型の両方のAxSpAにおいて有効であるため、TNFが十分に奏効しない患者に標的を絞った選択肢を提供し、人気を集めています。

HLA-B27遺伝子検査、MRIを用いた炎症評価、バイオマーカープロファイリングにより、早期診断と層別化治療が可能となります。疾患の不均一性の理解が進むにつれ、リウマチ専門医はAxSpAと機械的背部痛を鑑別し、治療方針を調整するために、これらのツールを活用するようになってきています。目に見えるX線変化の前に診断を確定できることは、タイムリーな介入を開始し、不可逆的な関節損傷を回避する上で極めて重要です。

ASAS、EULAR、ACRなどの団体による最新の治療ガイドラインは、治療アプローチを標準化し、専門医への早期紹介を奨励しています。非ステロイド性抗炎症薬（NSAIDs）から開始し、効果が不十分な場合には生物学的製剤に移行し、理学療法と生活習慣の改善を組み合わせるという段階的なエスカレーションのプロトコールが、臨床的意思決定の指針となっています。このような枠組みは、支払側の方針を調整し、先進治療へのアクセスの遅れを減らし、多様なヘルスケア環境における長期的な疾患コントロールを改善するのに役立っています。

どのような患者層、地域力学、アクセスモデルがAxSpA市場の治療需要を牽引しているか？

AxSpAは主に20代から40代に発症し、労働参加率の低下、欠勤、長期障害により社会的・経済的影響を強調する層です。X線画像診断によらないAxSpAの女性は、しばしば非典型的な症状を呈し、診断の遅れに直面します。このため、性別に配慮したスクリーニングを改善し、プライマリケア提供者の臨床的疑いを高める取り組みが活発化しています。

地域的には、欧州と北米が診断と治療の普及でリードしており、これは専門医の密度、高度な診断インフラ、公的・私的保険制度による生物学的製剤への幅広いアクセスに支えられています。アジア太平洋市場、特に日本と韓国では、啓蒙キャンペーンとリウマチ診療能力への投資により診断率が上昇しています。新興市場では、生物学的製剤へのアクセスは遅れているもの、非生物学的製剤による治療量の拡大や、早期発見と助成金による治療を強化するための政府出資による試験的プログラムの開始が進んでいます。

生物学的製剤による治療に関連する費用の障壁に対処するため、アクセスモデルが進化しています。バイオシミラーは、より低価格で治療の選択肢を広げ、患者の適用範囲を広げ、国の償還制度に組み込むことを可能にしています。価値に基づく価格設定の枠組みやリスク分担契約は、治療費と現実のアウトカムを一致させるために検討されています。一方、患者支援プログラムやデジタルヘルス支援ツールは、治療アドヒアランスを向上させ、遠隔地や十分なサービスを受けていない集団における継続的な疾患モニタリングを可能にしています。

医薬品開発パイプライン、デジタルモニタリングツール、マルチモーダルケアモデルは市場展望をどのように形成しているか？

AxSpAの薬剤開発パイプラインは、JAK-STATシグナル伝達、GM-CSF阻害、新規サイトカイン経路を標的とした治験薬によって、TNFおよびIL-17経路以外にも多様化しています。特に経口低分子は、投与が容易であること、治療を早期段階や生物学的製剤未使用集団に拡大できる可能性があることから注目されています。臨床試験では、疾患サブタイプ、HLA-B27の状態、および生物学的製剤への曝露歴によって層別化し、反応の差をよりよく理解し、治療順序を最適化することがますます増えています。

症状追跡、治療アドヒアランス、疾患活動性モニタリングのためのデジタルツールは、患者エンゲージメントを強化し、データ駆動型ケアモデルを可能にしています。モバイルアプリ、ウェアラブル、AIベースの意思決定支援システムは、痛み、こわばり、睡眠障害、可動性を長期にわたって追跡するために、リウマチ科のワークフローに統合されつつあります。これらのプラットフォームは、遠隔診察、治療調整、疾患フレアの早期発見をサポートし、リアルタイムの管理と長期的な転帰の追跡を向上させています。

薬物治療と理学療法、心理的サポート、生活習慣への介入を組み合わせた複合的なケアモデルは、公的・私的ヘルスケアシステムの双方で普及しつつあります。AxSpAの慢性的で多面的な性質が明らかになるにつれ、リウマチ専門医、リハビリテーション医、心理学者、プライマリケア提供者間のケア連携が重視されています。このような統合モデルは、患者が報告するアウトカムを改善するだけでなく、ヘルスケアの利用や全体的なケアコストを削減します。

軸性脊椎関節炎（AXSPA）市場の成長を促進する要因は何か？

AxSpA市場は、診断精度、生物学的製剤の技術革新、ヘルスケアシステムに対する認識が、早期かつ継続的な治療により長期的な利益をもたらす、管理可能な慢性疾患として再定義されることで拡大しています。過少診断から積極的な疾患モニタリングへのシフトは、より良い患者層別化と治療の調整を可能にしています。

主な成長促進要因としては、現役世代における有病率の上昇、生物学的製剤とバイオシミラーへのアクセス拡大、世界のガイドラインの整合化、早期段階での介入に対する支払者の償還意欲の高まりなどが挙げられます。デジタルヘルスツールと協調ケアモデルの統合は、市場の成熟と患者中心のイノベーションをさらに強化しています。

慢性炎症性疾患がヘルスケアの優先事項の最前線に躍り出る中、軸性脊椎関節炎は、早期発見、精密治療、統合ケアが自己免疫疾患管理の長期的アウトカムを再定義するモデルとなり得るだろうか。

セグメント

タイプ（強直性脊椎炎、非放射線性軸椎関節炎）

調査対象企業の例（注目の44社）

  • AbbVie Deutschland GmbH & Co. KG
  • AbbVie Inc.
  • Acelyrin, Inc.
  • Affibody AB
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Galapagos NV
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc（GSK）
  • Inmagene Biopharmaceuticals
  • Janssen Biotech, Inc.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP34672

Global Axial Spondyloarthritis (AXSPA) Market to Reach US$8.4 Billion by 2030

The global market for Axial Spondyloarthritis (AXSPA) estimated at US$6.4 Billion in the year 2024, is expected to reach US$8.4 Billion by 2030, growing at a CAGR of 4.6% over the analysis period 2024-2030. Ankylosing Spondylitis, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$5.3 Billion by the end of the analysis period. Growth in the Non-Radiographic Axial Spondyloarthritis segment is estimated at 6.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.7 Billion While China is Forecast to Grow at 7.2% CAGR

The Axial Spondyloarthritis (AXSPA) market in the U.S. is estimated at US$1.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 7.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.2% and 4.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.

Global Axial Spondyloarthritis (AxSpA) Market - Key Trends & Drivers Summarized

Why Is Axial Spondyloarthritis Gaining Visibility as a High-Burden Chronic Condition Requiring Early Diagnosis and Long-Term Therapeutic Management?

Axial spondyloarthritis (AxSpA) is drawing increased clinical and commercial focus as its prevalence and long-term impact on patient quality of life become more widely recognized. This inflammatory rheumatic disease primarily affects the spine and sacroiliac joints, manifesting as chronic back pain, stiffness, and reduced mobility. Despite its disabling nature, AxSpA remains underdiagnosed or misdiagnosed for years due to symptom overlap with non-inflammatory back pain and lack of early imaging-based confirmation.

The disease encompasses two subsets-radiographic AxSpA (ankylosing spondylitis) and non-radiographic AxSpA-both of which can progress toward spinal fusion and irreversible joint damage if not adequately managed. The burden on working-age adults is particularly significant, with functional impairment, fatigue, and associated comorbidities such as uveitis, psoriasis, and inflammatory bowel disease further compounding healthcare complexity. These factors underscore the need for early, accurate diagnosis and sustained access to disease-modifying therapies.

Growing awareness campaigns, improvements in MRI-based diagnostic protocols, and revised clinical guidelines from rheumatology societies are helping increase recognition of AxSpA across healthcare systems. As more patients are identified earlier in their disease journey, demand for effective long-term therapeutic solutions is rising. Payers and healthcare providers are increasingly treating AxSpA as a priority chronic condition requiring integrated care models, long-term monitoring, and outcome-driven therapy optimization.

How Are Biologic Therapies, Precision Diagnostics, and Treatment Guidelines Advancing Patient Outcomes in AxSpA?

Biologic therapies-particularly tumor necrosis factor (TNF) inhibitors and interleukin-17 (IL-17) inhibitors-have become the cornerstone of AxSpA treatment for patients who do not respond adequately to NSAIDs. These agents not only reduce inflammation and alleviate symptoms but also help slow structural damage progression. IL-17 inhibitors, such as secukinumab and ixekizumab, are gaining traction due to their efficacy in both radiographic and non-radiographic forms of AxSpA, providing a targeted alternative for TNF-inadequate responders.

Precision diagnostics are advancing treatment decisions, with HLA-B27 genetic testing, MRI-based inflammation assessment, and biomarker profiling enabling earlier diagnosis and stratified care. As understanding of disease heterogeneity improves, rheumatologists are increasingly leveraging these tools to differentiate AxSpA from mechanical back pain and tailor treatment pathways. The ability to confirm diagnosis prior to visible radiographic changes is critical in initiating timely intervention and avoiding irreversible joint damage.

Updated treatment guidelines from entities such as ASAS, EULAR, and ACR are standardizing care approaches and encouraging early referral to specialists. Stepwise escalation protocols-starting with NSAIDs, moving to biologics upon inadequate response, and integrating physiotherapy and lifestyle modifications-are guiding clinical decision-making. These frameworks are helping align payer policies, reduce delays in access to advanced therapies, and improve long-term disease control in diverse healthcare settings.

Which Patient Demographics, Regional Dynamics, and Access Models Are Driving Therapeutic Demand in the AxSpA Market?

AxSpA primarily affects individuals in their 20s to 40s, a demographic that underscores its societal and economic impact due to reduced workforce participation, absenteeism, and long-term disability. Gender-related differences in presentation and disease progression are influencing diagnosis and treatment patterns, as women with non-radiographic AxSpA often present with atypical symptoms and face delayed diagnosis. This has catalyzed efforts to improve gender-sensitive screening and raise clinical suspicion among primary care providers.

Regionally, Europe and North America lead in diagnosis and treatment adoption, supported by specialist density, advanced diagnostic infrastructure, and broad access to biologics through public and private insurance systems. Asia-Pacific markets, particularly Japan and South Korea, are seeing increased diagnosis rates due to awareness campaigns and investment in rheumatology capacity. Emerging markets, while lagging in biologic accessibility, are expanding non-biologic treatment volumes and initiating government-funded pilot programs to enhance early detection and subsidized care.

Access models are evolving to address cost barriers associated with biologic treatment. Biosimilars are expanding therapeutic options at lower price points, enabling broader patient coverage and inclusion in national reimbursement schemes. Value-based pricing frameworks and risk-sharing agreements are being explored to align therapy costs with real-world outcomes. Meanwhile, patient assistance programs and digital health support tools are improving treatment adherence and enabling continuous disease monitoring in remote or underserved populations.

How Are Drug Development Pipelines, Digital Monitoring Tools, and Multimodal Care Models Shaping the Market Outlook?

The drug development pipeline for AxSpA is diversifying beyond TNF and IL-17 pathways, with investigational therapies targeting JAK-STAT signaling, GM-CSF inhibition, and novel cytokine pathways. Oral small molecules, in particular, are drawing attention for their ease of administration and potential to expand treatment to earlier stages or biologic-naive populations. Clinical trials are increasingly stratifying by disease subtype, HLA-B27 status, and prior biologic exposure to better understand differential responses and optimize treatment sequencing.

Digital tools for symptom tracking, treatment adherence, and disease activity monitoring are enhancing patient engagement and enabling data-driven care models. Mobile apps, wearables, and AI-based decision support systems are being integrated into rheumatology workflows to track pain, stiffness, sleep disruption, and mobility over time. These platforms are supporting remote consultations, treatment adjustments, and early identification of disease flares-improving real-time management and long-term outcome tracking.

Multimodal care models that combine pharmacological treatment with physiotherapy, psychological support, and lifestyle interventions are gaining traction in both public and private healthcare systems. As the chronic and multifaceted nature of AxSpA becomes more apparent, care coordination between rheumatologists, physiatrists, psychologists, and primary care providers is being emphasized. These integrated models not only improve patient-reported outcomes but also reduce healthcare utilization and overall cost of care.

What Are the Factors Driving Growth in the Axial Spondyloarthritis (AxSpA) Market?

The AxSpA market is expanding as diagnostic precision, biologic innovation, and healthcare system awareness converge to reframe the condition as a manageable chronic disease with tangible long-term benefits from early and sustained treatment. The shift from underdiagnosis to proactive disease monitoring is enabling better patient stratification and therapy alignment.

Key growth drivers include rising prevalence among working-age populations, expanding access to biologics and biosimilars, global guideline harmonization, and increasing payer willingness to reimburse early-stage intervention. The integration of digital health tools and coordinated care models is further reinforcing market maturity and patient-centric innovation.

As chronic inflammatory diseases move to the forefront of healthcare priorities, could axial spondyloarthritis become a model for how early detection, precision therapy, and integrated care redefine long-term outcomes in autoimmune disease management?

SCOPE OF STUDY:

The report analyzes the Axial Spondyloarthritis (AXSPA) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Ankylosing Spondylitis, Non-Radiographic Axial Spondyloarthritis)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • AbbVie Deutschland GmbH & Co. KG
  • AbbVie Inc.
  • Acelyrin, Inc.
  • Affibody AB
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Galapagos NV
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc (GSK)
  • Inmagene Biopharmaceuticals
  • Janssen Biotech, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Axial Spondyloarthritis (AXSPA) - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness and Diagnostic Advancements Throw the Spotlight on Axial Spondyloarthritis Management
    • Growth in Biologic and Targeted Synthetic DMARD Pipelines Spurs Development of Disease-Modifying Treatments
    • Expansion of Diagnostic Imaging Access Improves Early Detection and Reduces Diagnostic Delays
    • Adoption of Multidisciplinary Treatment Models Supports Integrated Care Across Rheumatology and Rehabilitation
    • Increased Focus on Patient-Reported Outcome Measures Enhances Personalized Treatment Planning
    • Use of AI in Image Interpretation and Disease Progression Tracking Supports Clinical Decision-Making
    • Growth in Patient Advocacy and Education Drives Demand for Timely Diagnosis and Access to Therapy
    • Global Guidelines Supporting Early Biologic Intervention Create Opportunities for Market Expansion
    • OEMs Developing Oral Small Molecules for AXSPA Address Adherence Challenges in Injectable Therapies
    • Digital Health Tools and Telemedicine Platforms Improve Disease Monitoring and Treatment Compliance
    • Rising Prevalence of AXSPA Among Younger Adults Fuels Long-Term Market Potential for Chronic Management
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Axial Spondyloarthritis (AXSPA) Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Axial Spondyloarthritis (AXSPA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Ankylosing Spondylitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Ankylosing Spondylitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Ankylosing Spondylitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Non-Radiographic Axial Spondyloarthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Non-Radiographic Axial Spondyloarthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Non-Radiographic Axial Spondyloarthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Axial Spondyloarthritis (AXSPA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: USA 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: Canada 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • JAPAN
    • Axial Spondyloarthritis (AXSPA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: Japan 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • CHINA
    • Axial Spondyloarthritis (AXSPA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: China 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • EUROPE
    • Axial Spondyloarthritis (AXSPA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Axial Spondyloarthritis (AXSPA) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: Europe 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Europe 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • FRANCE
    • Axial Spondyloarthritis (AXSPA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: France 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • GERMANY
    • Axial Spondyloarthritis (AXSPA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Germany 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Italy 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Axial Spondyloarthritis (AXSPA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: UK 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Spain 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Russia 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Rest of Europe 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Axial Spondyloarthritis (AXSPA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Axial Spondyloarthritis (AXSPA) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Asia-Pacific 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Axial Spondyloarthritis (AXSPA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Australia 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • INDIA
    • Axial Spondyloarthritis (AXSPA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: India 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: South Korea 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Axial Spondyloarthritis (AXSPA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Axial Spondyloarthritis (AXSPA) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Latin America 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Latin America 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Argentina 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Brazil 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Mexico 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Rest of Latin America 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Axial Spondyloarthritis (AXSPA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Axial Spondyloarthritis (AXSPA) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Middle East 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Middle East 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Iran 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Israel 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Saudi Arabia 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: UAE 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Middle East 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030
  • AFRICA
    • Axial Spondyloarthritis (AXSPA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Axial Spondyloarthritis (AXSPA) by Type - Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Africa 15-Year Perspective for Axial Spondyloarthritis (AXSPA) by Type - Percentage Breakdown of Value Sales for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis for the Years 2015, 2025 & 2030

IV. COMPETITION